PCI Biotech Holding ASA (OSL: PCIB)
Norway
· Delayed Price · Currency is NOK 1.402
+0.070 (5.26%)
Nov 21, 2024, 3:50 PM CET
PCI Biotech Holding ASA Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Other Revenue | 6 | 2.99 | 4.75 | 6.27 | 7.37 | 9.39 | Upgrade
|
| Revenue | 6 | 2.99 | 4.75 | 6.27 | 7.37 | 9.39 | Upgrade
|
| Revenue Growth (YoY) | 114.86% | -37.05% | -24.28% | -14.86% | -21.55% | -2.01% | Upgrade
|
| Gross Profit | 6 | 2.99 | 4.75 | 6.27 | 7.37 | 9.39 | Upgrade
|
| Selling, General & Admin | 8.83 | 9.6 | 16.44 | 20.6 | 13.92 | 14.88 | Upgrade
|
| Research & Development | 14.96 | 15.63 | 44.76 | 71.71 | 75.57 | 83.31 | Upgrade
|
| Operating Expenses | 23.79 | 25.23 | 61.2 | 92.3 | 89.49 | 98.2 | Upgrade
|
| Operating Income | -17.8 | -22.24 | -56.45 | -86.03 | -82.12 | -88.8 | Upgrade
|
| Interest Expense | -0.1 | -0.16 | -0.13 | -0.09 | -0.4 | -0.51 | Upgrade
|
| Interest & Investment Income | 1.99 | 2.09 | 1.24 | 0.64 | 1.85 | 2.4 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | -2.5 | 8.5 | -1.6 | Upgrade
|
| Other Non Operating Income (Expenses) | -0 | -0 | 0.24 | -0.41 | -0.07 | -0.24 | Upgrade
|
| Pretax Income | -15.91 | -20.32 | -55.1 | -88.39 | -72.24 | -88.75 | Upgrade
|
| Net Income | -15.91 | -20.32 | -55.1 | -88.39 | -72.24 | -88.75 | Upgrade
|
| Net Income to Common | -15.91 | -20.32 | -55.1 | -88.39 | -72.24 | -88.75 | Upgrade
|
| Shares Outstanding (Basic) | 37 | 37 | 37 | 37 | 37 | 37 | Upgrade
|
| Shares Outstanding (Diluted) | 37 | 37 | 37 | 37 | 37 | 37 | Upgrade
|
| Shares Change (YoY) | - | - | - | 0.11% | -0.01% | 34.14% | Upgrade
|
| EPS (Basic) | -0.43 | -0.54 | -1.48 | -2.37 | -1.94 | -2.38 | Upgrade
|
| EPS (Diluted) | -0.43 | -0.54 | -1.48 | -2.37 | -1.94 | -2.38 | Upgrade
|
| Free Cash Flow | -14.59 | -14.97 | -59.04 | -68.65 | -81.31 | -87.1 | Upgrade
|
| Free Cash Flow Per Share | -0.39 | -0.40 | -1.58 | -1.84 | -2.18 | -2.34 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -296.63% | -743.85% | -1188.36% | -1371.42% | -1114.55% | -945.52% | Upgrade
|
| Profit Margin | -265.24% | -679.43% | -1159.89% | -1409.07% | -980.44% | -944.91% | Upgrade
|
| Free Cash Flow Margin | -243.24% | -500.67% | -1242.99% | -1094.34% | -1103.56% | -927.39% | Upgrade
|
| EBITDA | -17.81 | -22.22 | -56.43 | -84.11 | -80.52 | -88.45 | Upgrade
|
| D&A For EBITDA | -0.02 | 0.02 | 0.02 | 1.92 | 1.6 | 0.35 | Upgrade
|
| EBIT | -17.8 | -22.24 | -56.45 | -86.03 | -82.12 | -88.8 | Upgrade
|
| Revenue as Reported | 2.99 | 2.99 | 4.75 | 6.27 | 7.37 | 9.39 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.